A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
- Citation:
- Cancer vol 119 (21) 3797-804
- Year:
- 2013
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 3
- Parents:
- 458
- Children:
- None
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- Barbara W Grant Sin-Ho Jung Jeffrey L Johnson Lale Kostakoglu Eric Hsi John C Byrd Jeffrey Jones John P Leonard S Eric Martin Bruce D Cheson
- Networks:
- Study
- CALGB-50701
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- FLIPI score, epratuzumab, follicular lymphoma, monoclonal antibody, rituximab